PCSA

Processa Pharmaceuticals, Inc. Common

3.36

USD

PCSA Earnings Reports

Positive Surprise Ratio

PCSA beat 7 of 20 last estimates.

35%

Next Report

Date of Next Report

Mar 18, 2026

Estimate for Q4 25 (Revenue/ EPS)

-$1.40

Implied change from Q3 25 (Revenue/ EPS)

-20.00%

Implied change from Q4 24 (Revenue/ EPS)

-92.43%

Processa Pharmaceuticals, Inc. Common earnings per share and revenue

On Nov 06, 2025, PCSA reported earnings of -1.75 USD per share (EPS) for Q3 25, beating the estimate of -2.04 USD, resulting in a 14.22% surprise. Revenue reached --, compared to an expected --, with a --% difference. The market reacted with a -3.20% price change (close before vs. close after earnings).

Looking ahead to Q4 25, 4 analysts forecast an EPS of -1.40 USD, with revenue projected to reach -- USD, implying an decrease of -20.00% EPS, and -- of --% in Revenue from the last quarter.

FAQ

What were Processa Pharmaceuticals, Inc. Common's earnings and revenue for the latest quarter Q3 2025?

For Q3 2025, Processa Pharmaceuticals, Inc. Common reported EPS of -$1.75, beating estimates by 14.22%, and revenue of --, -- -- expectations.

How did the market react to Processa Pharmaceuticals, Inc. Common's Q3 2025 earnings?

The stock price moved down -3.2%, changed from $7.90 before the earnings release to $7.64 the day after.

When is Processa Pharmaceuticals, Inc. Common expected to report next?

The next earning report is scheduled for Mar 18, 2026.

What are the forecasts for Processa Pharmaceuticals, Inc. Common's next earnings report?

Based on 4 analysts, Processa Pharmaceuticals, Inc. Common is expected to report EPS of -$1.40 and revenue of -- for Q4 2025.

Which companies are reporting earnings today?

Check FXEmpire's Earnings Calendar for today's list of reporting companies.